ClinicalTrials.gg
RecruitingNCT06475261Updated Mar 7, 2025

Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy

An observational study in Oxygen Deficiency, Acute Kidney Injury and Ovarian Carcinoma, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Hypoxia with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Hypoxia · Italy.

Started
2024
with 1 other
Observational
7 of 26
3 open now
Registered
22nd of 26
by date
Lead sponsor
5 of 26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 26 studies in Hypoxia with a site in Italy, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 22nd registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

4 of the 26 studies in Hypoxia with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypoxia with a site in Italy, or all of them as a file.
02

Study summary

Tissue oximetry obtained from peripheral muscle measures the state of tissue oxygenation of various organs and, as already widely described in the literature, can be used to measure the state of kidney's tissue oxygenation. However, there is no evidence in the existing scientific literature on the use of muscle tissue oximetry in patients undergoing cytoreductive surgery for ovarian cancer with hyperthermic intraperitoneal chemotherapy.

The primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer.

Read the detailed description

Tissue oximetry obtained from peripheral muscle can be used to measure the state of kidney's tissue oxygenation.

50 Adult female patients ASA 1-2 undergoing cytoreductive surgery with laparoscopic or laparotomy technique (for ovarian cancer) associated with hyperthermic intraperitoneal chemotherapy will be enrolled.

The primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage (according to the AKIN and KIDGO classification) in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer.

Secondary objectives are:

  • describe the variation in muscle tissue oximetry and hemodynamic parameters (systolic, mean, diastolic blood pressure) during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy .
  • describe the variation in renal function values (blood urea nitrogen, creatinine) and serum electrolytes (sodium, potassium, chloremia, calcemia) in the post-operative period (from the first to the seventh postoperative day).
03

Conditions studied

  • Oxygen Deficiency
  • Acute Kidney Injury
  • Ovarian Carcinoma

Keywords

  • Tissue Oximetry
  • Hyperthermic Intraperitoneal Chemotherapy
  • Acute Kidney Injury
  • Hemodynamics parameters
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult female patients ASA 1-2 undergoing cytoreductive surgery with laparoscopic or laparotomy technique (for ovarian cancer) associated with hyperthermic intraperitoneal chemotherapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • American Society Anesthesiologists (ASA) Classification 1-2
  • Cytoreductive surgery for ovarian cancer with laparoscopic or laparotomic technique with Hypertermic Intraperitoneal Chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • ASA > or = 3
  • Cytoreductive surgery without hyperthermic intraperitoneal chemotherapy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceTissue Oximetry with ForeSight

    Evaluation of a correlation between average intraoperative muscle tissue oximetry and postoperative renal damage in patients undergoing cytoreductive surgery with HIPEC for ovarian cancer

    Also known as: Hemodynamics parameters with Hemosphere

06

What researchers measure

Primary outcomes

  1. Correlation between intraoperative tissue oximetry and postoperative acute renal injury.

    An intraoperative mean tissue oximetry value of 65% or less is considered to predict cellular damage. Postoperative renal injury is classified according to AKIN and KIDGO criteria.

    Time frame: Tissue oximetry is defined as TWA (time-weighted average) value resulted by values recorded intraoperatively every 20 minutes.

Secondary outcomes

  1. Tissue oximetry

    Describing intraoperative variation of tissue oximetry expressed in percent.

    Time frame: TWA value resulted by intraoperative values recorded every 20 minutes during surgery.

  2. Tissue oximetry during hyperthermic intraperitoneal chemotherapy

    Describing variation of tissue oximetry during hyperthermic intraperitoneal chemotherapy, expressed in percent.

    Time frame: TWA value resulted by intraoperative values recorded every 20 minutes during hyperthermic intraperitoneal chemotherapy .

  3. Emodinamic parameters (systolic, mean and diastolic pressures)

    Describing mean values of intraoperative arterial pressure (systolic, mean and diastolic pressures), expressed in mmHg

    Time frame: Intraoperatively, a mean value resulted by values recorded every 20 minutes during surgery.

  4. Emodinamic parameters (systolic, mean and diastolic pressures) during hyperthermic intraperitoneal chemotherapy

    Describing mean values of arterial pressure (systolic, mean and diastolic pressures), expressed in mmHg, during hyperthermic intraperitoneal chemotherapy

    Time frame: A mean value resulted by values recorded every 20 minutes during hyperthermic intraperitoneal chemotherapy

  5. Serum Creatinine level

    Mean value of creatinine, daily assessed for the first 7 postoperative days, expressed in mg/dL

    Time frame: From 1st to 7th postoperative days

  6. Serum Blood urea nitrogen level

    Mean value of Serum blood urea nitrogen, daily assessed for the first 7 postoperative days, expressed in mg/dL

    Time frame: From 1st to 7th postoperative day

  7. Serum sodium level

    Mean values of Serum sodium, daily assessed for the first 7 postoperative days, expressed in mmol/L

    Time frame: From 1st to 7th postoperative day

  8. Serum Potassium level

    Mean values of Serum potassium, daily assessed for the first 7 postoperative days, expressed in mmol/L

    Time frame: From 1st to 7th postoperative day

  9. Serum Chloride level

    Mean values of Serum chloride, daily assessed for the first 7 postoperative days, expressed in mmol/L

    Time frame: From 1st to 7th postoperative day

  10. Serum Calcium level

    Mean values of Serum calcium, daily assessed for the first 7 postoperative days, expressed in mmol/L

    Time frame: From 1st to 7th postoperative day

07

Study locations

1 of 1 sites recruiting
  • Policlinico "A. Gemelli" IRCCS
    Rome, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2025, 13 months after the start.

Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's planned 13 months is below that.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jun 26, 2024
StartActual
Jul 27, 2024
Primary completionEst.
Aug 31, 2025
CompletionEst.
Sep 30, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06475261
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jul 27, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Mar 7, 2025

Study contacts

Stefano Catarci, MD
Contact
stefano.catarci@policlinicogemelli.it
0630153744
Stefano Catarci, MD
principal investigator · FPG IRCCS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion